Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Plasma cell 1Gynecologic 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Anus Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dehydroepiandrosterone × Gynecologic × Clear all
NCT07407647 2026-04-21

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
25 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡